BSY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bentley Systems (BSY) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown solid financial growth in Q4 2025, the technical indicators suggest a neutral to bearish trend, and there are no strong trading signals or recent positive news catalysts to support immediate action. Analysts' ratings are mixed, with price targets generally lowered, and the options data indicates a lack of strong bullish sentiment. Given the user's impatience and unwillingness to wait for optimal entry points, holding off on buying BSY for now is the most prudent decision.
The technical indicators for BSY show a bearish trend. The MACD is below zero and negatively contracting, indicating weak momentum. The RSI is neutral at 56.039, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level (R1: 35.416), which could limit further upside in the short term.
Strong Q4 2025 financial performance: Revenue increased by 11.94% YoY, net income rose by 17.08% YoY, and EPS grew by 12.50% YoY.
Gross margin improved to 79.8%, up 2.02% YoY, indicating operational efficiency.
Analysts acknowledge durable growth opportunities in data centers and minimal near-term AI disruption risk.
Mixed analyst ratings with multiple firms lowering price targets, citing macroeconomic factors and multiple compression.
Technical indicators suggest a bearish trend, with no clear upward momentum.
Lack of recent news or event-driven catalysts to drive the stock higher.
Options data indicates moderate caution among traders, with limited bullish sentiment.
In Q4 2025, Bentley Systems reported strong financial growth. Revenue increased by 11.94% YoY to $391.58M, net income rose by 17.08% YoY to $58.62M, and EPS improved by 12.50% YoY to $0.18. Gross margin also increased to 79.8%, reflecting improved operational efficiency.
Analyst ratings are mixed. Barclays raised the price target to $49, while Piper Sandler and UBS lowered their targets to $42 and $40, respectively, citing concerns about macro factors and multiple compression. Mizuho and Rosenblatt maintain positive outlooks with price targets of $50, while Oppenheimer highlights a healthy top- and bottom-line beat but reduced the target to $43. Overall, there is no strong consensus for a bullish outlook.
